Actovegin in the treatment of patients with cognitive impairments in the chronic cerebral ischemia

Chronic cerebral ischemia is a common problem especially among the elderly. It gradually leads to social disability and invalidisation of those patients. One of the possible pathogenic mechanisms of this condition is the endothelial dysfunction. Thus, the attempt to repair the latter is one of the treatment goals. It is assumed that actovegin improves tissue microcirculation by expanding precapillary zone – the main marker of the metabolic activity in the microvascular endothelium. Actovegin activates anaerobic metabolism and oxygenation in endotheliocytes. Patients, treated by actovegin, showed improvement of cognitive functions and psycho-emotional state. Due to the absence of proteins, the drug has good tolerance and low toxicity.